Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Drug Profile

Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Alternative Names: CTX-023; CTX-033; CTX-1003; CX 188; CX 2005; EGFR Probody Drug Conjugate; J43 antibody; Probodies; Probody™ cancer therapeutics - Bristol-Myers Squibb

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb; CytomX Therapeutics
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders
  • Discontinued Inflammation

Most Recent Events

  • 12 Jan 2017 Discontinued for Inflammation in USA (Parenteral)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 28 May 2014 Protease-activated monoclonal antibodies licensed to Bristol-Myers Squibb worldwide for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top